Docoh
Loading...

VCEL Vericel

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.

Company profile

Ticker
VCEL
Exchange
Website
CEO
Dominick Colangelo
Employees
Incorporated
Location
Fiscal year end
Former names
AASTROM BIOSCIENCES INC
SEC CIK
IRS number
943096597

VCEL stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Vericel earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 58.37M 58.37M 58.37M 58.37M 58.37M 58.37M
Cash burn (monthly) (positive/no burn) (positive/no burn) 1.1M (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) n/a n/a 4.5M n/a n/a n/a
Cash remaining n/a n/a 53.86M n/a n/a n/a
Runway (months of cash) n/a n/a 48.9 n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
21 Jul 21 Sean C. Flynn Common Stock Sell Dispose S No Yes 55.01 2,800 154.03K 2,419
21 Jul 21 Sean C. Flynn Common Stock Option exercise Aquire M No No 16.25 2,800 45.5K 5,219
21 Jul 21 Sean C. Flynn Stock Option Common Stock Option exercise Dispose M No No 16.25 2,800 45.5K 137,200
15 Jul 21 Sean C. Flynn Common Stock Sell Dispose S No Yes 51.1786 10,000 511.79K 2,419
15 Jul 21 Sean C. Flynn Common Stock Option exercise Aquire M No No 16.25 10,000 162.5K 12,419
15 Jul 21 Sean C. Flynn Stock Option Common Stock Option exercise Dispose M No No 16.25 10,000 162.5K 140,000
12 Jul 21 Halpin Michael Common Stock Sell Dispose S No Yes 53.5438 20,000 1.07M 5,623
12 Jul 21 Halpin Michael Common Stock Option exercise Aquire M No No 2.65 20,000 53K 25,623
12 Jul 21 Halpin Michael Stock Option Common Stock Option exercise Dispose M No No 2.65 20,000 53K 27,063
30 Jun 21 Joseph Anthony Mara Jr Common Stock Payment of exercise Dispose F No No 52.5 1,174 61.64K 5,848

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 201 166 +21.1%
Opened positions 62 43 +44.2%
Closed positions 27 13 +107.7%
Increased positions 57 50 +14.0%
Reduced positions 66 56 +17.9%
13F shares
Current Prev Q Change
Total value 5.42B 2.06B +162.9%
Total shares 49.48M 45.42M +8.9%
Total puts 64.4K 46.7K +37.9%
Total calls 113.5K 55.2K +105.6%
Total put/call ratio 0.6 0.8 -32.9%
Largest owners
Shares Value Change
BLK Blackrock 7.26M $403.34M +120.5%
Brown Capital Management 4.57M $253.87M +13.6%
RTW Investments 4.52M $250.95M 0.0%
Vanguard 2.94M $163.36M +26.0%
Fred Alger Management 2.72M $151.32M NEW
WDR Waddell & Reed Financial 2.69M $149.48M -2.8%
STT State Street 2.43M $134.99M +11.1%
FHI Federated Hermes 1.54M $85.42M +12.0%
WFC Wells Fargo & Co. 1.04M $57.52M -14.5%
Next Century Growth Investors 1.01M $55.89M -26.6%
Largest transactions
Shares Bought/sold Change
BLK Blackrock 7.26M +3.97M +120.5%
Fred Alger Management 2.72M +2.72M NEW
UBS UBS Group AG - Registered Shares 10.01K -908.2K -98.9%
Great Point Partners 0 -900K EXIT
Granahan Investment Management 376.23K -715.61K -65.5%
Vanguard 2.94M +607.67K +26.0%
Kopp Family Office 574.08K -576.66K -50.1%
Brown Capital Management 4.57M +547.28K +13.6%
BNP Paribas Asset Management Holding 452.37K -544.17K -54.6%
Artisan Partners Limited Partnership 958.45K +443.8K +86.2%

Financial report summary

?
Management Discussion
  • Our net loss for the three months ended March 31, 2021 and 2020 totaled $3.3 million and $4.7 million, respectively.
  • Net revenue increased for the three months ended March 31, 2021 compared to the same period in 2020, driven by strong volume growth for both MACI and Epicel. Additionally, during the three months ended March 31, 2021, we recorded $0.9 million of revenue associated with delivery of NexoBrid to BARDA for emergency response preparedness.
  • Net revenue for the three months ended March 31, 2021 and 2020 are shown below.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: assure, autumn, bromelain, Canada, cessation, cGMP, Chemistry, CMC, competitive, compliance, cycle, damage, degree, dissipated, diversion, enriched, fallen, fell, fringe, guide, human, implied, ineffective, infection, inoculate, Israel, Litigation, lockdown, mentioned, Mexico, month, NaN, outcome, outset, overseen, pathway, payable, pivotal, Practice, prevent, professional, pronounced, proteolytic, quality, Reform, render, rent, resuming, risen, rose, senior, sought, speak, spring, strong, summer, Taiwan, transmission, turn, unrecognized, urging, usage, vaccine, wave, widely, worsening, wrong
Removed: anonyme, apply, assessed, assumption, automated, banning, base, beginning, book, calling, candidate, cardiomyopathy, China, clarity, close, consistent, construction, DCM, declared, developed, dilated, discretionary, downturn, exempt, expanded, factor, framework, French, fund, heart, implemented, improve, incorporate, incurred, infrastructure, initiate, instituting, instruction, instrument, interim, involve, liquidity, location, lost, lower, lowering, macroeconomic, marrow, measure, measuring, minimize, modify, multicellular, occurring, organization, originated, paragraph, preapproval, President, proprietary, purpose, Quarterly, rapidly, recent, recognize, recommended, reducing, representing, Sanofi, scalable, shelter, spending, stage, statement, supportable, suspending, system, temporarily, Topic, unanticipated, undue, unique, workforce, Wuhan